๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› California
Clinical trial register · United States · industry-sponsored

Clinical Trials in California, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 9112 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 23 Sep 2026, 03:16 UTC
9112
Studies in scope
industry-sponsored, all four open statuses
4950
Recruiting now
open to new participants
2202
Lead sponsors
across recruiting studies
Top states
California 5295 Florida 4397 Illinois 2479 Georgia 2346 Arizona 2231
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca230 Eli Lilly and Company150 AbbVie142 Merck Sharp & Dohme LLC130 Novartis Pharmaceuticals113
State
California5295 Florida4397 Illinois2479 Georgia2346 Arizona2231
All 51 states
Target enrolment
to

Trials with a site in California

5295 of 9112 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
NCT06623422Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC
Phase 3
680
Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois, Indiana
2024-10-21
Active, closed
Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis
NCT06450886Inclusion Body Myositis (IBM)
Abcuro, Inc.
Phase 2/3
270
Arizona, California, Connecticut, Massachusetts, New York, North Carolina, Ohio, Pennsylvania
2024-10-21
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Eli Lilly and Company
Phase 1
750
Alabama, Arizona, California, Connecticut, Illinois, Indiana, Massachusetts, Michigan
2024-10-21
Recruiting
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
NCT06382155Idiopathic Short Stature
BioMarin Pharmaceutical
Phase 2
100
California, District of Columbia, Florida, Georgia, Idaho, Iowa, Kentucky, Louisiana
2024-10-21
Active, closed
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
NCT06643728Obesity, Overweight
Eli Lilly and Company
Phase 2
252
Alabama, California, Florida, Hawaii, Illinois, Mississippi, Pennsylvania, Washington
2024-10-21
Recruiting
Controlled Desaturation Study for Perin Health Patch Validation
NCT06680700Oxygen Saturation Measurement
Perin Health Devices
Observational
25
California
2024-10-21
Recruiting
ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)
NCT06430385Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
Ionis Pharmaceuticals, Inc.
Phase 1/2
48
California, Colorado, Maryland, Massachusetts, Minnesota, Pennsylvania, Tennessee, Texas
2024-10-21
Recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
NCT06544499Primary Immune Thrombocytopenia (ITP)
argenx
Phase 3
69
Arizona, California, Colorado, Connecticut, District of Columbia, Illinois, Iowa, Louisiana
2024-10-18
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786Colorectal Neoplasms
Janssen Research & Development, LLC
Phase 3
1,000
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-10-18
Recruiting
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
NCT06619860Diabetic Peripheral Neuropathic Pain
Vertex Pharmaceuticals Incorporated
Phase 2
300
Alabama, California, Colorado, Florida, Georgia, Idaho, Illinois, Michigan
2024-10-18
By invitation
A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )
NCT06559176Chronic Granulomatous Disease, Granulomatous Disease, Chronic
Prime Medicine, Inc.
Phase 1/2
12
California, Maryland, Tennessee
2024-10-17
Active, closed
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
NCT06643481Amyotrophic Lateral Sclerosis (ALS)
Novartis Pharmaceuticals
Phase 2
251
California, Florida, Georgia, Kansas, Massachusetts, Nebraska, New York, North Carolina
2024-10-17
Recruiting
J-Valve Transfemoral Pivotal Study
NCT06455787Aortic Valve Regurgitation, Aortic Valve Disease Mixed
JC Medical, Inc., an affiliate of Edwards Lifesciences LLC
Not applicable
194
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Kansas
2024-10-17
Active, closed
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
NCT06625320Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc.
Phase 3
500
Arizona, California, Colorado, Florida, Hawaii, Illinois, Maryland, Massachusetts
2024-10-16
Active, closed
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
NCT06637371Asthma
Amgen
Phase 1
21
California, Florida, Georgia, Maryland, Massachusetts, Minnesota, North Carolina, Oklahoma
2024-10-16
Active, closed
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis
NCT06598462Eosinophilic Esophagitis (EoE)
Uniquity One (UNI)
Phase 2
184
Alabama, Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois
2024-10-16
Recruiting
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT06549790Relapsed/Refractory Acute Myeloid Leukemia
Nerviano Medical Sciences
Phase 1
124
California, Colorado, Delaware, Georgia, Minnesota, Ohio, Texas
2024-10-16
Recruiting
A Study of Bevonescein in Patients Undergoing Abdominopelvic Surgery
NCT06662097Surgery, Nerve Injury, Imaging
Alume Biosciences, Inc.
Phase 2
64
California
2024-10-16
Active, closed
A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
NCT06581575Herpes Zoster (HZ), Infectious Diseases, Shingles
Immorna Biotherapeutics, Inc.
Phase 2
467
Arizona, California, Illinois, Nebraska, New Jersey, South Carolina, Texas
2024-10-16
Active, closed
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
NCT06564844Non-small Cell Lung Cancer
AstraZeneca
Phase 3
25
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky
2024-10-15
Active, closed
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
NCT06641076Arthritis, Psoriatic
MoonLake Immunotherapeutics AG
Phase 3
960
Arizona, California, Florida, Illinois, Louisiana, Maryland, Michigan, North Carolina
2024-10-15
Recruiting
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFฮฑ Inadequate Response
NCT06641089Arthritis, Psoriatic
MoonLake Immunotherapeutics AG
Phase 3
600
Arizona, Arkansas, California, Florida, Georgia, Illinois, Louisiana, Maryland
2024-10-15
Recruiting
Study of ATX-01 in Participants With DM1
NCT06300307Myotonic Dystrophy 1
ARTHEx Biotech S.L.
Phase 1/2
56
California, Florida, Iowa, Kansas, Virginia
2024-10-15
Recruiting
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Novartis Pharmaceuticals
Phase 1
162
Alabama, California, Florida, Massachusetts, Michigan, Minnesota, Texas, Washington
2024-10-15
Recruiting
LIVERAGEโ„ข: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Boehringer Ingelheim
Phase 3
1,800
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana
2024-10-14
Active, closed
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
NCT06553768Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
Mirum Pharmaceuticals, Inc.
Phase 3
90
California, Illinois, New York, Ohio, Texas, Utah
2024-10-14
Recruiting
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
NCT06486454Liver Neoplasms, Primary Liver Cancer, Secondary Liver Cancer, Tumor Liver
HistoSonics, Inc.
Observational
5,000
California, Florida, Georgia, Illinois, Louisiana, Maryland, Massachusetts, Michigan
2024-10-14
Recruiting
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
NCT06447168Primary Biliary Cholangitis
Ipsen
Observational
424
California, Colorado, Connecticut, Florida, Massachusetts, New Jersey, New York, North Carolina
2024-10-14
Active, closed
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
NCT06453213Focal Onset Seizure
SK Life Science, Inc.
Phase 4
49
Arizona, Arkansas, California, Connecticut, Florida, Idaho, Kentucky, Louisiana
2024-10-14
Active, closed
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
NCT06388564Chronic Graft-versus-host-disease
Incyte Corporation
Phase 2
130
Arizona, California, Colorado, Connecticut, Florida, Illinois, Maryland, Missouri
2024-10-11
Recruiting
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
NCT06581432Solid Tumours
Boehringer Ingelheim
Phase 2
588
Alaska, Arizona, California, Connecticut, Florida, Illinois, Indiana, Maryland
2024-10-11
Recruiting
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
NCT06619990Ulcerative Colitis (UC)
Xencor, Inc.
Phase 1/2
270
Arizona, California, Florida, Kentucky, Mississippi, New York, North Carolina, Ohio
2024-10-10
Recruiting
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
NCT06598943Ulcerative Colitis, Ulcerative Colitis Chronic
Eli Lilly and Company
Phase 2
143
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Illinois, Louisiana
2024-10-10
Active, closed
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
NCT06516952Prurigo Nodularis
Incyte Corporation
Phase 3
349
Alabama, Arizona, Arkansas, California, Florida, Illinois, Indiana, Michigan
2024-10-10
Active, closed
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
NCT06625060Episodic Migraine, Chronic Migraine
Ipsen
Phase 2
670
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Louisiana
2024-10-10
Active, closed
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
NCT06516965Prurigo Nodularis
Incyte Corporation
Phase 3
346
Arizona, California, Florida, Kentucky, Maryland, Massachusetts, Michigan, New Hampshire
2024-10-10
Active, closed
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
NCT06544655Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1
213
Arizona, California, Michigan, South Dakota, Texas
2024-10-10
Recruiting
A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
NCT06525636X-linked Hypophosphatemia
Kyowa Kirin Co., Ltd.
Phase 1/2
39
California, Connecticut, Indiana, Minnesota, Tennessee
2024-10-09
Recruiting
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06470048Diffuse Cutaneous Systemic Sclerosis
Novartis Pharmaceuticals
Phase 2
200
Arizona, California, Florida, Illinois, Louisiana, Michigan, New York, Tennessee
2024-10-09
Active, closed
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
NCT06630286HIV-1-infection
Gilead Sciences
Phase 3
609
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-10-09
Active, closed
Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)
NCT05417789TGCT
SynOx Therapeutics Limited
Phase 3
128
California, Ohio, Texas, Washington
2024-10-09
Active, closed
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1
NCT06630299HIV-1-Infection
Gilead Sciences
Phase 3
600
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-10-08
Active, closed
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
NCT06672055SARS-CoV2, COVID-19
Vaxart
Phase 2
5,485
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-10-08
Recruiting
Phase 1/Phase 2 Study of ACR-2316 in Specific Advanced Solid Tumors
NCT06667141Specific Advanced Solid Tumors
Acrivon Therapeutics
Phase 1/2
100
Arizona, California, Colorado, Florida, Massachusetts, Michigan, New York, North Carolina
2024-10-08
Recruiting
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
NCT06602479Migraine
AbbVie
Phase 2
488
Alabama, California, Florida, Kentucky, New York, Rhode Island, South Carolina, Texas
2024-10-07
Active, closed
A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) - Long Lesion Cohort
NCT06492174In-Stent Restenosis
Boston Scientific Corporation
Phase 3
20
Arizona, California, Georgia, Michigan, New York, Ohio, Pennsylvania, Rhode Island
2024-10-07
Recruiting
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
NCT06598306Extensive Stage Small Cell Lung Cancer
Amgen
Phase 1
220
California, Illinois, Michigan, South Dakota, Texas, Washington
2024-10-07
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression โ‰ฅ 1%
NCT06561386Non-small Cell Lung Cancer
Bristol-Myers Squibb
Phase 3
1,000
Alabama, Arizona, California, Colorado, Florida, Idaho, Illinois, Kansas
2024-10-07
Recruiting
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06417814Metastatic Non-small Cell Lung Cancer
AstraZeneca
Phase 3
744
Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Kentucky
2024-10-04
Recruiting
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants
NCT06625671Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus
DualityBio Inc.
Phase 1/2
148
California, Florida, New York, Texas
2024-10-04
Recruiting
THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUSโ„ข) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension
NCT06559891Hypertension
SoniVie Inc.
Not applicable
261
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Illinois, Louisiana
2024-10-03
Recruiting
A Study of BG-C477 in Participants With Advanced Solid Tumors
NCT06596473Advanced Solid Tumors
BeOne Medicines
Phase 1
310
Arizona, California, Colorado, Connecticut, Illinois, Kansas, Mississippi, New Jersey
2024-10-03
Recruiting
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
NCT05947955Acute Respiratory Distress Syndrome, Infections
BioAegis Therapeutics Inc.
Phase 2
600
California, Georgia, Illinois, Kentucky, Minnesota, Missouri, Nebraska, New York
2024-10-03
Recruiting
A Clinical Trial to Assess the Efficacy and Tolerance of a Berberine-based Nutraceutical Formula to Aid Blood Sugar Regulation and Metabolism
NCT06700915Metabolism Disorder, Nutraceutical
Ultimate International, Inc.
Not applicable
80
California
2024-10-03
Recruiting
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
NCT06568237Multiple System Atrophy
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
350
California, District of Columbia, Florida, Illinois, Kansas, Massachusetts, Michigan, Minnesota
2024-10-02
Recruiting
ALTO-100 in Bipolar Disorder With Depression (BD-D)
NCT06656416Bipolar Disorder I or II With a Major Depressive Episode
Alto Neuroscience
Phase 2
200
Arizona, Arkansas, California, Colorado, Florida, Georgia, Maryland, Nebraska
2024-10-02
Recruiting
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
NCT06568692Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer
Processa Pharmaceuticals
Phase 2
90
Arizona, California, Florida, Indiana, Maryland, New Jersey, New York, Ohio
2024-10-02
Recruiting
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
NCT06561048Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
Corvus Pharmaceuticals, Inc.
Phase 3
150
California, Connecticut, Florida, Georgia, Illinois, Iowa, Maryland, Massachusetts
2024-10-02
Active, closed
SIMPLAAFY Clinical Trial
NCT06521463Atrial Fibrillation, Stroke, Bleeding
Boston Scientific Corporation
Not applicable
1,857
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-10-01
Recruiting
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
NCT06628908Diabetic Peripheral Neuropathic Pain
Vertex Pharmaceuticals Incorporated
Phase 3
1,100
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2024-10-01
Active, closed
Efficacy of a Dietary Supplement Powder Formula (Daily Ultimate Essentials) in an Adult Population.
NCT06655597Dietary Assessment
Prenetics Global
Phase 4
60
California
2024-10-01
Active, closed
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
NCT06506955Advanced/Metastatic Cancer
Taiho Oncology, Inc.
Phase 2/3
15
California
2024-10-01
Recruiting
Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Knee Osteoarthritis
NCT06608134Osteoarthritis, Knee
R3 Medical Research
Phase EARLY_PHASE1
120
Arizona, California, New York, Texas
2024-10-01
Recruiting
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06510374Intermediate Risk Non-Muscle Invasive Bladder Cancer
Ferring Pharmaceuticals
Phase 3
454
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2024-10-01
Recruiting
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
NCT06545955Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Ferring Pharmaceuticals
Phase 3
250
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-10-01
Recruiting
Urine Metabolites in the Diagnosis of Disease
NCT06710067Colorectal Cancer, Small Intestinal Bacterial Overgrowth Syndrome (SIBO), Crohn Disease, Celiac Disease
Luventix, Inc.
Observational
1,250
California
2024-10-01
Not yet open
Investigating Engagement Patterns and Participation Trends Among Liposarcoma Patients
NCT06039046Liposarcoma
Power Life Sciences Inc.
Observational
500
California
2024-10
Not yet open
Navigating the Clinical Research Process for Lymphoma
NCT06070246Lymphoma
Power Life Sciences Inc.
Observational
500
California
2024-10
Not yet open
Assessing the Experience of Patients Undergoing Follicular Lymphoma Clinical Research
NCT06049485Follicular Lymphoma
Power Life Sciences Inc.
Observational
500
California
2024-10
Not yet open
Insights Into Participating in Studies for Bone Cancer
NCT06070259Bone Cancer
Power Life Sciences Inc.
Observational
500
California
2024-10
Not yet open
Patient Perspectives in Mantle Cell Lymphoma Clinical Research
NCT06049472Mantle Cell Lymphoma
Power Life Sciences Inc.
Observational
500
California
2024-10
Not yet open
Understanding Engagement Trends in Chondrosarcoma Clinical Trials
NCT06029478Chondrosarcoma
Power Life Sciences Inc.
Observational
500
California
2024-10
Not yet open
Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials
NCT06029465Rhabdomyosarcoma
Power Life Sciences Inc.
Observational
500
California
2024-10
Not yet open
Determining Patterns In Trial Experiences of Recurrent Prostate Cancer Patients
NCT06070272Recurrent Prostate Cancer
Power Life Sciences Inc.
Observational
500
California
2024-10
Not yet open
Exploring Merkel Cell Carcinoma Clinical Trial Engagement Patterns
NCT06039033Merkel Cell Carcinoma
Power Life Sciences Inc.
Observational
500
California
2024-10
Not yet open
Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients
NCT06070285Recurrent Ovarian Cancer
Power Life Sciences Inc.
Observational
500
California
2024-10
Active, closed
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
NCT06473779Severe Asthma
AstraZeneca
Phase 3
326
California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Oklahoma, Texas
2024-09-30
Recruiting
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
NCT06551142Neoplasms
GlaxoSmithKline
Phase 1
845
California, Colorado, Connecticut, Indiana, Massachusetts, Michigan, New Jersey, South Carolina
2024-09-30
Recruiting
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
NCT06613698Liver Diseases, Alcoholic
GlaxoSmithKline
Phase 2
393
Arizona, California, Florida, Georgia, Indiana, Kansas, Louisiana, Michigan
2024-09-27
Recruiting
Registry for Stage 2 Type 1 Diabetes
NCT06481904Type 1 Diabetes
Sanofi
Observational
200
California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2024-09-27
Recruiting
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT06492616Breast Cancer
Stemline Therapeutics, Inc.
Phase 3
4,220
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-09-27
Recruiting
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787Alzheimer Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
406
Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Michigan, Mississippi
2024-09-26
Recruiting
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
NCT06539507Netherton Syndrome
BioCryst Pharmaceuticals
Phase 1
78
California, Connecticut, Illinois, Indiana
2024-09-26
Active, closed
TraNsvenous TrIcuspid Valve ReplacemenT With LuX-Valve Plus System (TRINITY-US)
NCT06568003Tricuspid Regurgitation (TR)
Jenscare Innovation Inc.
Not applicable
15
California, Michigan, New York
2024-09-26
Active, closed
A Multi-Centre Study in Patients Undergoing Total Hip Arthroplasty With the Smith+Nephew CATALYSTEMโ„ข Primary Hip System
NCT06564636Total Hip Arthroplasty (THA), Osteoarthritis, Degenerative Joint Disease, Inflammatory Arthritis
Smith & Nephew, Inc.
Observational
119
California, Connecticut, Florida, Illinois, New York, North Carolina
2024-09-26
Active, closed
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
NCT06660394Dravet Syndrome
Longboard Pharmaceuticals
Phase 3
96
Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Maryland
2024-09-25
Recruiting
A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)
NCT06462235Gram-negative Bacterial Infection
Pfizer
Phase 2
48
California, Colorado, Indiana, Kentucky, Massachusetts, North Carolina, Texas
2024-09-25
Recruiting
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
NCT06525220Head and Neck Squamous Cell Carcinoma
Merus B.V.
Phase 3
700
Alabama, California, Delaware, District of Columbia, Florida, Georgia, Illinois, Kentucky
2024-09-25
Recruiting
Registry Study to Observe Long-term Safety of Vamorolone (AGAMREEยฎ) in Patients With Duchenne Muscular Dystrophy-SUMMIT
NCT06564974Duchenne Muscular Dystrophy
Catalyst Pharmaceuticals, Inc.
Observational
250
Arizona, Arkansas, California, District of Columbia, Florida, Illinois, Indiana, Kansas
2024-09-25
Active, closed
ADVENT Post Approval Study
NCT06431815Paroxysmal Atrial Fibrillation
Boston Scientific Corporation
Observational
228
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Louisiana, Massachusetts
2024-09-25
Active, closed
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants โ‰ฅ18 Years of Age for the Prevention of Acute Gastroenteritis
NCT06592794Acute Gastroenteritis, Norovirus Acute Gastroenteritis
ModernaTX, Inc.
Phase 3
37,864
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2024-09-24
Active, closed
A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)
NCT06436742Congenital Myasthenic Syndrome, CMS
argenx
Phase 1
15
California, Illinois
2024-09-24
Active, closed
Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough
NCT06504446Refractory or Unexplained Chronic Cough
Nocion Therapeutics
Phase 2
455
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2024-09-24
Active, closed
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
NCT06481891Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
Lexicon Pharmaceuticals
Phase 3
500
Arizona, California, Florida, Georgia, Illinois, Indiana, Maryland, Massachusetts
2024-09-24
Active, closed
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Hoffmann-La Roche
Phase 3
338
Arizona, California, Connecticut, Florida, Illinois, Maine, Massachusetts, Michigan
2024-09-23
Recruiting
Dehydrated Human Amnion Membrane and Standard of Care Versus Standard of Care Alone in Nonhealing Diabetic Foot Ulcers
NCT06550596Diabetic Foot, Ulcer Foot, Foot Ulcer, Diabetic Foot Ulcer
Axolotl Biologix
Not applicable
100
California
2024-09-23
Recruiting
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
NCT06413680Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors
Regeneron Pharmaceuticals
Phase 1/2
240
California, Connecticut, Illinois, Michigan, New York, North Carolina, Pennsylvania, Texas
2024-09-23
Recruiting
A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT
NCT05171894Port-wine Birthmarks, Port-Wine Stain, Nevus Flammeus
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 2
84
California, Florida, Maryland, Pennsylvania
2024-09-21
Active, closed
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
NCT06553027Parkinson Disease
Cerevance
Phase 3
330
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Kansas
2024-09-20
Recruiting
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
NCT06633016Major Depressive Disorder
Autobahn Therapeutics, Inc.
Phase 2
230
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts
2024-09-20
Rows per page Showing 2301–2400 of 5295
Previous 22 23 24 25 26 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-usa/state/california?page=24

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,112 studies in total at the last sync on 23 Sep 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,295 of those studies with a site in California.

How many clinical trials are recruiting in California?

2,760 of the 5,295 studies on this page are recruiting new participants as of the 23 Sep 2026, 03:16 UTC sync. A further 162 have not yet opened recruitment, 2,205 are active but closed to new participants, and 168 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.